It’s Tuesday at the 2017 JP Morgan Healthcare conference in San Francisco.
Each day of #JPM17 we’re doing a rolling blog post which we’re updating throughout the day with commentary and insights on the company presentations we’re covering.
While we’re not giving a blow-by-blow account, many companies have the slides readily available, we will be commenting on noteworthy news, and what we learn about pharma/biotech corporate strategy going into 2017.
For those of you who like to catch up with the final summary of each day’s highlights, you can read our post around Day 1 here (Link).
Yesterday we also published a thought leader interview we did with Dr Stephan Grupp, Director of the Cancer Immunotherapy Program at CHOP about some of the latest CAR T cell data and emerging issues we heard at #ASH16 last month (Link). Do check it out!